Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
3.
Inflamm Res ; 66(5): 389-398, 2017 May.
Article in English | MEDLINE | ID: mdl-28238167

ABSTRACT

OBJECTIVE AND DESIGN: Alzheimer's disease (AD) is associated with amyloid plaques (Aß) and hyperphosphorylated tau protein tangles in the brain. We investigated the possible neuroprotective role of flavocoxid, a dual inhibitor of cyclooxygenases-1/2 (COX-1/2) and 5-Lipoxygenase (5-LOX), in triple-transgenic (3xTg-AD) mice. SUBJECTS: Mice were 3 months at the beginning of the study. TREATMENT: Animals received once daily for 3-month saline solution or flavocoxid (20 mg/kg/ip). METHODS: Morris water maze was used to assess learning and memory. Histology was performed to evidence Aß plaques and neuronal loss, while inflammatory proteins were determined by western blot analysis. RESULTS: Saline-treated 3xTg-AD mice showed an impairment in spatial learning and memory (assessed at 6 months of age), and increased expression of inflammatory and apoptotic molecules. Treatment of 3xTg-AD mice with flavocoxid reduced: (1) learning and memory loss; (2) the increased eicosanoid production and the phosphorylation level of amyloid precursor protein (APP-pThr668), Aß 1-42, p-tau (pThr181), pERK, and the activation of the NLRP3 inflammasome; (3) Aß plaques; and (4) neuronal loss, compared to saline-treated animals. CONCLUSIONS: Pharmacological blockade of both COX-1/2 and 5-LOX was able to counteract the progression of AD by targeting pathophysiological mechanisms up- and downstream of Aß and tau.


Subject(s)
Alzheimer Disease/drug therapy , Catechin/therapeutic use , Cyclooxygenase Inhibitors/therapeutic use , Lipoxygenase Inhibitors/therapeutic use , Neuroprotective Agents/therapeutic use , Alzheimer Disease/metabolism , Amyloid beta-Protein Precursor/metabolism , Animals , Brain/drug effects , Brain/metabolism , Brain/pathology , Catechin/pharmacology , Cyclooxygenase Inhibitors/pharmacology , Dinoprostone/metabolism , Disease Models, Animal , Drug Combinations , Interleukin-1beta/metabolism , Leukotriene B4/metabolism , Lipoxygenase Inhibitors/pharmacology , Male , Maze Learning/drug effects , Memory/drug effects , Mice, Transgenic , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Neuroprotective Agents/pharmacology , tau Proteins/metabolism
4.
Int J Mol Sci ; 18(3)2017 Mar 22.
Article in English | MEDLINE | ID: mdl-28327526

ABSTRACT

Benign prostatic hyperplasia (BPH) treatment includes the apoptosis machinery modulation through the direct inhibition of caspase cascade. We previously demonstrated that Serenoa repens (Ser) with lycopene (Ly) and selenium (Se) reawakened apoptosis by reducing survivin and neuronal apoptosis inhibitory protein (NAIP) levels in rats. The aim of this study was to evaluate the effectiveness of Ser-Se-Ly association on survivin and NAIP expression in BPH patients. Ninety patients with lower urinary tract symptoms (LUTS) due to clinical BPH were included in this randomized, double-blind, placebo-controlled trial. Participants were randomly assigned to receive placebo (Group BPH + placebo, n = 45) or Ser-Se-Ly association (Group BPH + Ser-Se-Ly; n = 45) for 3 months. At time 0, all patients underwent prostatic biopsies. After 3 months of treatment, they underwent prostatic re-biopsy and specimens were collected for molecular, morphological, and immunohistochemical analysis. After 3 months, survivin and NAIP were significantly decreased, while caspase-3 was significantly increased in BPH patients treated with Ser-Se-Ly when compared with the other group. In BPH patients treated with Ser-Se-Ly for 3 months, the glandular epithelium was formed by a single layer of cuboidal cells. PSA showed high immunoexpression in all BPH patients and a focal positivity in Ser-Se-Ly treated patients after 3 months. Evident prostate specific membrane antigen (PSMA) immunoexpression was shown in all BPH patients, while no positivity was present after Ser-Se-Ly administration. Ser-Se-Ly proved to be effective in promoting apoptosis in BPH patients.


Subject(s)
Inhibitor of Apoptosis Proteins/metabolism , Neuronal Apoptosis-Inhibitory Protein/metabolism , Prostatic Hyperplasia/metabolism , Prostatic Hyperplasia/pathology , Aged , Antigens, Surface/genetics , Antigens, Surface/metabolism , Apoptosis/drug effects , Biomarkers , Carotenoids/pharmacology , Gene Expression Regulation/drug effects , Glutamate Carboxypeptidase II/genetics , Glutamate Carboxypeptidase II/metabolism , Humans , Immunohistochemistry , Inhibitor of Apoptosis Proteins/genetics , Lycopene , Male , Middle Aged , Neuronal Apoptosis-Inhibitory Protein/genetics , Plant Extracts/pharmacology , Prostatic Hyperplasia/etiology , Prostatic Hyperplasia/prevention & control , Selenium/pharmacology , Selenium Compounds/pharmacology , Serenoa/chemistry , Survivin
5.
Int J Mol Sci ; 17(6)2016 Jun 22.
Article in English | MEDLINE | ID: mdl-27338365

ABSTRACT

Reactive oxygen species (ROS) represent reactive products belonging to the partial reduction of oxygen. It has been reported that ROS are involved in different signaling pathways to control cellular stability. Under normal conditions, the correct function of redox systems leads to the prevention of cell oxidative damage. When ROS exceed the antioxidant defense system, cellular stress occurs. The cellular redox impairment is strictly related to tumorigenesis. Tumor cells, through the generation of hydrogen peroxide, tend to the alteration of cell cycle phases and, finally to cancer progression. In adults, the most common form of primary malignant brain tumors is represented by gliomas. The gliomagenesis is characterized by numerous molecular processes all characterized by an altered production of growth factor receptors. The difficulty to treat brain cancer depends on several biological mechanisms such as failure of drug delivery through the blood-brain barrier, tumor response to chemotherapy, and intrinsic resistance of tumor cells. Understanding the mechanisms of ROS action could allow the formulation of new therapeutic protocols to treat brain gliomas.


Subject(s)
Antineoplastic Agents/pharmacology , Antioxidants/pharmacology , Brain Neoplasms/metabolism , Glioma/metabolism , Reactive Oxygen Species/metabolism , Animals , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/therapeutic use , Antioxidants/pharmacokinetics , Antioxidants/therapeutic use , Blood-Brain Barrier/metabolism , Brain Neoplasms/drug therapy , Drug Resistance, Neoplasm , Glioma/drug therapy , Humans
6.
Int J Mol Sci ; 17(8)2016 Aug 11.
Article in English | MEDLINE | ID: mdl-27529214

ABSTRACT

Benign prostatic hyperplasia (BPH) is a chronic condition common in older men that can result in bothersome lower urinary tract symptoms. The molecular mechanisms and networks underlying the development and the progression of the disease are still far from being fully understood. BPH results from smooth muscle cell and epithelial cell proliferation, primarily within the transition zone of the prostate. Apoptosis and inflammation play important roles in the control of cell growth and in the maintenance of tissue homeostasis. Disturbances in molecular mechanisms of apoptosis machinery have been linked to BPH. Increased levels of the glycoprotein Dickkopf-related protein 3 in BPH cause an inhibition of the apoptosis machinery through a reduction in B cell lymphoma (Bcl)-2 associated X protein (Bax) expression. Inhibitors of apoptosis proteins influence cell death by direct inhibition of caspases and modulation of the transcription factor nuclear factor-κB. Current pharmacotherapy targets either the static component of BPH, including finasteride and dutasteride, or the dynamic component of BPH, including α-adrenoceptor antagonists such as tamsulosin and alfuzosin. Both these classes of drugs significantly interfere with the apoptosis machinery. Furthermore, phytotherapic supplements and new drugs may also modulate several molecular steps of apoptosis.


Subject(s)
Apoptosis/drug effects , Endocrine System/metabolism , Prostatic Hyperplasia/drug therapy , Prostatic Hyperplasia/metabolism , Dutasteride/therapeutic use , Endocrine System/drug effects , Finasteride/therapeutic use , Humans , Male , Quinazolines/therapeutic use , Sulfonamides/therapeutic use , Tamsulosin , Urological Agents/therapeutic use
7.
J Pharmacol Exp Ther ; 355(3): 370-80, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26407722

ABSTRACT

We investigated the role of the nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3) inflammasome during testis ischemia and reperfusion injury (TI/R) in wild-type (WT) and NLRP3 knock-out (KO) mice. WT and KO mice underwent 1 hour testicular ischemia followed by 4 hours and 1 and 7 days of reperfusion or a sham TI/R. Furthermore, two groups of WT mice were treated at the beginning of reperfusion and up to 7 days with two inflammasome inhibitors, BAY 11-7082 (20 mg/kg i.p.) or Brilliant Blue G (45.5 mg/kg i.p.), or vehicle. Animals were killed with a pentobarbital sodium overdose at 4 hours and 1 and 7 days, and bilateral orchidectomies were performed. Biochemical and morphologic studies were carried out in all groups. TI/R in WT mice significantly increased caspase-1 and interleukin (IL)-1ß mRNA after 4 hours and IL-18 mRNA at 1 day of reperfusion (P ≤ 0.05). There was also a significant increase in caspase-3 and terminal deoxynucleotidyl transferase-mediated digoxigenin-deoxyuridine nick-end labeling-positive cells, marked histologic damage, and altered spermatogenesis in WT mice in both testes after 1 and 7 days of reperfusion. KO TI/R mice, WT TI/R BAY 11-7082, and Brilliant Blue G treated mice showed a significant reduced IL-1ß and IL-18 mRNA expression, blunted caspase-1 and -3 expression, minor histologic damages, low terminal deoxynucleotidyl transferase-mediated digoxigenin-deoxyuridine nick-end labeling activity, and preserved spermatogenesis. These data suggest that the activation of NLRP3 plays a key role in TI/R, and its inhibition might represent a therapeutic target for the management of patients with unilateral testicular torsion.


Subject(s)
Carrier Proteins/genetics , Inflammasomes/genetics , Reperfusion Injury/genetics , Reperfusion Injury/pathology , Spermatogenesis/genetics , Testicular Diseases/genetics , Testicular Diseases/pathology , Animals , Apoptosis/drug effects , Caspase 1/metabolism , Caspase 3/metabolism , Interleukin-18/biosynthesis , Interleukin-1beta/biosynthesis , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , NLR Family, Pyrin Domain-Containing 3 Protein , Nitriles/pharmacology , Orchiectomy , Rosaniline Dyes/pharmacology , Sulfones/pharmacology , Testis/pathology
8.
J Biomed Sci ; 21: 19, 2014 Mar 10.
Article in English | MEDLINE | ID: mdl-24606563

ABSTRACT

BACKGROUND: The apoptosis machinery is a promising target against benign prostatic hyperplasia (BPH). Inhibitors of apoptosis proteins (IAPs) modulate apoptosis by direct inhibition of caspases. Serenoa Repens (SeR) may be combined with other natural compounds such as Lycopene (Ly) and Selenium (Se) to maximize its therapeutic activity in BPH. We investigated the effects of SeR, Se and Ly, alone or in association, on the expression of four IAPs, cIAP-1, cIAP-2, NAIP and survivin in rats with experimental testosterone-dependent BPH. Moreover, caspase-3, interleukin-6 (IL-6) and prostate specific membrane antigen (PSMA) have been evaluated.Rats were administered, daily, with testosterone propionate (3 mg/kg/sc) or its vehicle for 14 days. Testosterone injected animals (BPH) were randomized to receive vehicle, SeR (25 mg/kg/sc), Se (3 mg/kg/sc), Ly (1 mg/kg/sc) or the SeR-Se-Ly association for 14 days. Animals were sacrificed and prostate removed for analysis. RESULTS: BPH animals treated with vehicle showed unchanged expression of cIAP-1 and cIAP-2 and increased expression of NAIP, survivin, caspase-3, IL-6 and PSMA levels when compared with sham animals. Immunofluorescence studies confirmed the enhanced expression of NAIP and survivin with a characteristic pattern of cellular localization. SeR-Se-Ly association showed the highest efficacy in reawakening apoptosis; additionally, this therapeutic cocktail significantly reduced IL-6 and PSMA levels. The administration of SeR, Se and Ly significantly blunted prostate overweight and growth; moreover, the SeR-Se-Ly association was most effective in reducing prostate enlargement and growth by 43.3% in treated animals. CONCLUSIONS: The results indicate that IAPs may represent interesting targets for drug therapy of BPH.


Subject(s)
Apoptosis/drug effects , Carotenoids/administration & dosage , Inhibitor of Apoptosis Proteins/administration & dosage , Prostatic Hyperplasia/drug therapy , Animals , Apoptosis Regulatory Proteins/biosynthesis , Carotenoids/chemistry , Gene Expression Regulation, Neoplastic/drug effects , Humans , Lycopene , Male , Phytotherapy , Prostatic Hyperplasia/pathology , Rats , Serenoa/chemistry
9.
Crit Care Med ; 40(3): 945-51, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22036855

ABSTRACT

OBJECTIVE: Treatment for traumatic brain injury remains elusive despite compelling evidence from animal models for a variety of therapeutic targets. Melanocortins have established neuroprotective effects against experimental ischemic stroke. We investigated whether melanocortin treatment of traumatic brain injury induces neuroprotection and promotes functional recovery. DESIGN: Randomized experiment. SETTING: Research laboratory at a university hospital. SUBJECTS: Male Sprague-Dawley rats (n = 215). INTERVENTIONS: Experimental rat model of diffuse traumatic brain injury, the impact-acceleration model. MEASUREMENT AND MAIN RESULTS: Brain tissue nitrites, phosphorylation level of extracellular signal-regulated kinases, and c-jun N-terminal kinases; and expression of active caspase-3, tumor necrosis factor-α, BAX, and Bcl-2 as well as serum levels of interleukin-6, high mobility group box-1, interleukin-10, and brain histologic damage were evaluated 24 or 48 hrs after the insult. Sensorimotor orientation and limb use were evaluated at day 7 and learning and memory at days 23-30 after injury. Posttraumatic treatment every 12 hrs with the melanocortin analog [Nle, D-Phe]-α-melanocyte-stimulating hormone (starting 3 or 6 hrs after injury) inhibited traumatic brain injury-induced upregulation of nitric oxide synthesis, phosphorylation level of extracellular signal-regulated kinases, phosphorylation level of c-jun N-terminal kinases, and active caspase-3; reduced expressions/levels of tumor necrosis factor-α, BAX, interleukin-6, and high mobility group box-1; and increased those of Bcl-2 and interleukin-10. These molecular changes were associated with a reduction in brain tissue damage, as highlighted by histopathological findings and improved functional recovery. Pretreatment with the melanocortin MC4 receptor antagonist HS024 abated the positive effects of [Nle, D-Phe]-α-melanocyte-stimulating hormone. CONCLUSIONS: Our data indicate that melanocortins protect against traumatic brain injury, in a broad time window and through activation of MC4 receptors, by counteracting the main traumatic brain injury-related mechanisms of damage. These findings could have major clinical implications.


Subject(s)
Brain Injuries/drug therapy , Brain Injuries/prevention & control , Melanocortins/therapeutic use , Animals , Male , Rats , Rats, Sprague-Dawley , Recovery of Function , Time Factors
10.
Arthritis Rheum ; 63(11): 3364-71, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21769841

ABSTRACT

OBJECTIVE: Broad antiinflammatory effects following adenosine A(2A) receptor stimulation have been demonstrated in acute inflammatory diseases, including arthritis. Polydeoxyribonucleotide (PDRN) activates the adenosine A(2A) receptor. This study was undertaken to investigate the effects of PDRN in collagen-induced arthritis (CIA) in mice. METHODS: Arthritis was induced in DBA/1 mice by an intradermal injection of 100 µl of bovine type II collagen in Freund's complete adjuvant. Mice were immunized a second time 21 days later. Control animals received 100 µl of a saline solution. Animals with CIA were randomized to receive one of the following: vehicle (1 ml/kg); PDRN (8 mg/kg intraperitoneally daily); 3,7-dimethyl-propargylxanthine (DMPX), a specific adenosine A(2A) receptor antagonist (0.1 mg/kg intraperitoneally daily); or PDRN plus DMPX. The treatment was initiated immediately after the second immunization and continued to day 45. Clinical evaluation of arthritis was performed throughout the study. On day 45, the animals were killed and the severity of arthritis was evaluated histologically. Cartilage expression and circulating levels of high mobility group box chromosomal protein 1 (HMGB-1), tumor necrosis factor α (TNFα), interleukin-6 (IL-6), and IL-10 were investigated. Inflammatory cytokine production was also evaluated in stimulated human chondrocytes treated with PDRN. RESULTS: PDRN treatment significantly ameliorated clinical signs of arthritis, improved histologic damage, reduced the cartilage expression and circulating levels of HMGB-1, TNFα, and IL-6, and enhanced IL-10 expression. The concomitant administration of DMPX and PDRN ablated the PDRN-induced protective effect in experimental arthritis. PDRN also reduced cytokine production from stimulated human chondrocytes. CONCLUSION: Our findings indicate that PDRN may represent a new alternative for the treatment of arthritis.


Subject(s)
Adenosine A2 Receptor Agonists/therapeutic use , Arthritis, Experimental/drug therapy , Cartilage, Articular/drug effects , Polydeoxyribonucleotides/therapeutic use , Adenosine A2 Receptor Agonists/pharmacology , Animals , Arthritis, Experimental/metabolism , Arthritis, Experimental/pathology , Cartilage, Articular/metabolism , Cartilage, Articular/pathology , Chondrocytes/metabolism , Chondrocytes/pathology , Collagen Type II/administration & dosage , HMGB1 Protein/metabolism , Interleukin-10/metabolism , Interleukin-6/metabolism , Male , Mice , Polydeoxyribonucleotides/pharmacology , Severity of Illness Index , Tumor Necrosis Factor-alpha/metabolism
11.
Crit Care ; 16(1): R32, 2012 Feb 22.
Article in English | MEDLINE | ID: mdl-22356547

ABSTRACT

INTRODUCTION: Cecal ligation and puncture (CLP) is an inflammatory condition that leads to multisystemic organ failure. Flavocoxid, a dual inhibitor of cyclooxygenase (COX-2) and 5-lipoxygenase (5-LOX), has been shown in vitro to possess antiinflammatory activity in lipopolysaccharide (LPS)-stimulated rat macrophages by reducing nuclear factor (NF)-κB activity and COX-2, 5-LOX and inducible nitric oxide synthase (iNOS) expression. The aim of this study was to evaluate the effects of flavocoxid in a murine model of CLP-induced polymicrobial sepsis. METHODS: C57BL/6J mice were subjected to CLP or sham operation. In a first set of experiments, an intraperitoneal injection of flavocoxid (20 mg/kg) or vehicle was administered 1 hour after surgery and repeated every 12 hours. Survival rate was monitored every 24 hours throughout 120 hours. Furthermore, additional groups of sham and CLP mice were killed 18 hours after surgical procedures for blood-sample collection and the lung and liver were collected for biomolecular, biochemical and histopathologic studies. RESULTS: COX-2, 5-LOX, tumor necrosis factor-α (TNF-α), interleukin (IL)-6, IL-10, extracellular-regulated-kinase 1/2 (ERK), JunN-terminal kinase (JNK), NF-κB, and ß-arrestin 2 protein expression were evaluated in lung and liver with Western blot analysis. In addition, leukotriene B4 (LTB4), prostaglandin E2 (PGE2), cytokines, and lipoxin A4 serum content were measured with an enzyme-linked immunosorbent assay (ELISA). Flavocoxid administration improved survival, reduced the expression of NF-κB, COX-2, 5-LOX, TNF-α and IL-6 and increased IL-10 production. Moreover, flavocoxid inhibited the mitogen-activated protein kinases (MAPKs) pathway, preserved ß-arrestin 2 expression, reduced blood LTB4, PGE2, TNF-α and IL-6, and increased IL-10 and lipoxin A4 serum levels. The treatment with flavocoxid also protected against the histologic damage induced by CLP and reduced the myeloperoxidase (MPO) activity in the lung and liver. CONCLUSIONS: Flavocoxid protects mice from sepsis, suggesting that this dual inhibitor may represent a promising approach in such a life-threatening condition.


Subject(s)
Catechin/therapeutic use , Cyclooxygenase 2 Inhibitors/therapeutic use , Lipoxygenase Inhibitors/therapeutic use , Sepsis/drug therapy , Animals , Arrestins/metabolism , Cytokines/blood , Cytokines/metabolism , Dinoprostone/blood , Disease Models, Animal , Drug Combinations , Extracellular Signal-Regulated MAP Kinases/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , Leukotriene B4/blood , Lipoxins/blood , Liver/metabolism , Liver/pathology , Lung/metabolism , Lung/pathology , Mice, Inbred C57BL , NF-kappa B/blood , Peroxidase/metabolism , Sepsis/metabolism , Sepsis/pathology , beta-Arrestin 2 , beta-Arrestins
12.
Surg Endosc ; 26(4): 984-9, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22038163

ABSTRACT

BACKGROUND: Experimental evidence suggests that laparoscopy could have reduced inflammatory sequelae compared with laparotomy following abdominal surgery for peritonitis. The aim of the present study is to investigate the possible beneficial effects of CO(2) insufflation on liver and lung expression of proinflammatory cytokines during sepsis. METHODS: Cecal ligation and puncture (CLP) was induced in Sprague-Dawley rats, and 6 h later rats were randomly subjected to CO(2) pneumoperitoneum (5-7 mmHg) or to laparotomy for 1 h. At the end of the CO(2) pneumoperitoneum or laparotomy procedures, animals were sacrificed, and liver and lung were removed and stored for molecular and histological analysis. RESULTS: Liver and lung expression of proinflammatory cytokines was significantly reduced in animals subjected to CO(2) pneumoperitoneum compared with laparotomy. In particular, tumor necrosis factor-alpha (TNF-α) protein expression was significantly reduced (p < 0.05) following CO(2) pneumoperitoneum compared with laparotomy procedures. Interleukin (IL)-6 protein expression was accordingly, markedly reduced (p < 0.05) following CO(2) pneumoperitoneum. Histological analysis showed a reduced inflammatory infiltrate in liver and lung from animals subjected to CO(2) pneumoperitoneum compared with laparotomy. CONCLUSIONS: Our results support the hypothesis that laparoscopic procedures reduce the inflammatory cascade, following peritoneal sepsis, via reduced expression of proinflammatory cytokines.


Subject(s)
Interleukin-6/metabolism , Liver/metabolism , Lung/metabolism , Peritonitis/metabolism , Pneumoperitoneum, Artificial/methods , Tumor Necrosis Factor-alpha/metabolism , Acute Lung Injury/prevention & control , Animals , Blotting, Western , Carbon Dioxide/administration & dosage , Laparoscopy/adverse effects , Laparotomy/adverse effects , Ligation/methods , Peritonitis/etiology , Rats , Rats, Sprague-Dawley , Sepsis/etiology , Sepsis/metabolism
14.
Curr Med Chem ; 24(35): 3879-3893, 2017 Nov 20.
Article in English | MEDLINE | ID: mdl-28762312

ABSTRACT

BACKGROUND: Cadmium (Cd) is a heavy metal particularly hazardous for human health, as it is highly diffused and, therefore, a ubiquitous environmental toxicant. In fact, in the general population, the main sources of exposure are food, cigarette smoking, inhalation of ambient air, drinking water, contaminated soil or dust. Furthermore, an occupational exposure usually involves human during mining, fume inhalation or manufacturing nickel-cadmium battery, electroplating and paint pigments that utilize Cd. METHODS: We undertook a structured search in literature about Cd. This metal is noxious on the cells of many organs, among which the kidney, the testis and the brain will be considered in this review. RESULTS: The toxic effects induced by Cd include many specific mechanisms, such as the oxidative stress, cellular death and inflammation. As no specific therapy for the prevention or treatment of the morbidity and mortality associated with Cd exposure is available, the state of the art of the therapeutic approaches is illustrated. CONCLUSION: Nowadays, a therapy able to counteract Cd toxicity is still lacking and the development of new therapeutic agents is requested.


Subject(s)
Brain/drug effects , Cadmium/toxicity , Environmental Pollutants/toxicity , Kidney/drug effects , Testis/drug effects , Animals , Antioxidants/pharmacology , Brain/metabolism , Environmental Pollutants/chemistry , Humans , Kidney/metabolism , Male , Oxidative Stress/drug effects , Signal Transduction/drug effects , Testis/metabolism
15.
Oncotarget ; 8(40): 68280-68290, 2017 Sep 15.
Article in English | MEDLINE | ID: mdl-28978116

ABSTRACT

Meningiomas are the most common tumors of the central nervous system, where the incidence is around 25% of all primary brain tumors. The optimal treatment is represented by total resection accompanied by the removal of the dura mater and bone when infiltrated by the tumor. The histological grading is the most important prognostic factor in the outcome. However, recurrences do occur in a significant proportion (10-25%) of cases, representing the most relevant clinical complication. Molecular therapies are providing to give different opportunities in the development of new treatments. The Dickkopf-related family of proteins includes four secretory proteins. The expression of the REIC/Dkk-3 gene is down-regulated in many tumor cell lines and could contribute to the immunomodulatory properties of the tissue microenvironment. An important role in carcinogenesis is played by Dickkopf protein-related protein 3, which is involved in embryonic development through its interaction and modulation of the pathway of the Wnt signal transduction. The mutations of this pathway are of clinical importance, because they lead to the onset of several cancers, including brain tumors, being also involved in tumor angiogenesis. The claudin-5, is an integral membrane protein, which regulate the permeability of the blood-brain barrier. In various pathological processes, including inflammation, trauma and tumor, claudin 5 regulate the change in endothelial or epithelial permeability, therefore, modification in claudin-5 expression may play a role in malignant transformation. The aim of our study is to demonstrate the role of Dkk-3 and claudin-5 in the pathogenesis of meningiomas. A more correct identification of the role of these proteins might suggest interesting and new molecular targets for future therapeutic protocols.

16.
Front Pharmacol ; 7: 537, 2016.
Article in English | MEDLINE | ID: mdl-28119612

ABSTRACT

Cadmium (Cd) impairs blood-testis barrier (BTB). Polydeoxyribonucleotide (PDRN), an adenosine A2A agonist, has positive effects on male reproductive system. We investigated the effects of PDRN on the morphological and functional changes induced by Cd in mice testes. Adult Swiss mice were divided into four groups: controls administered with 0.9% NaCl (1 ml/kg, i.p., daily) or with PDRN (8 mg/kg, i.p. daily), animals challenged with Cd chloride (CdCl2; 2 mg/kg, i.p, daily) and animals challenged with CdCl2 (2 mg/kg, i.p., daily) and treated with PDRN (8 mg/kg, i.p., daily). Experiments lasted 14 days. Testes were processed for biochemical, structural, and ultrastructural evaluation and hormones were assayed in serum. CdCl2 increased pERK 1/2 expression and Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) levels; it decreased testosterone (TE) and inhibin-B levels and induced structural damages in extratubular compartment and in seminiferous epithelium, with ultrastructural features of BTB disruption. Many TUNEL-positive germ cells were present. CdCl2 increased tubular TGF-ß3 immunoreactivity and reduced claudin-11, occludin, and N-cadherin immunoreactivity. PDRN administration reduced pERK 1/2 expression, FSH, and LH levels; it increased TE and inhibin-B levels, ameliorated germinal epithelium changes and protected BTB ultrastructure. Few TUNEL-positive germ cells were present and the extratubular compartment was preserved. Furthermore, PDRN decreased TGF-ß3 immunoreactivity and enhanced claudin-11, occludin, and N-cadherin immunoreactivity. We demonstrate a protective effect of PDRN on Cd-induced damages of BTB and suggest that PDRN may play an important role against Cd, particularly against its harmful effects on gametogenesis.

17.
Oxid Med Cell Longev ; 2016: 2183026, 2016.
Article in English | MEDLINE | ID: mdl-27127546

ABSTRACT

Ischemia and reperfusion (I/R) causes a reduction in arterial blood supply to tissues, followed by the restoration of perfusion and consequent reoxygenation. The reestablishment of blood flow triggers further damage to the ischemic tissue through reactive oxygen species (ROS) accumulation, interference with cellular ion homeostasis, and inflammatory responses to cell death. In normal conditions, ROS mediate important beneficial responses. When their production is prolonged or elevated, harmful events are observed with peculiar cellular changes. In particular, during I/R, ROS stimulate tissue inflammation and induce NLRP3 inflammasome activation. The mechanisms underlying the activation of NLRP3 are several and not completely elucidated. It was recently shown that NLRP3 might sense directly the presence of ROS produced by normal or malfunctioning mitochondria or indirectly by other activators of NLRP3. Aim of the present review is to describe the current knowledge on the role of NLRP3 in some organs (brain, heart, kidney, and testis) after I/R injury, with particular regard to the role played by ROS in its activation. Furthermore, as no specific therapy for the prevention or treatment of the high mortality and morbidity associated with I/R is available, the state of the art of the development of novel therapeutic approaches is illustrated.


Subject(s)
Inflammasomes/metabolism , Myocardium/metabolism , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Reactive Oxygen Species/metabolism , Reperfusion Injury/pathology , Animals , Brain/metabolism , Brain/pathology , Kidney/metabolism , Male , Reperfusion Injury/metabolism , Testis/metabolism , Testis/pathology
18.
Biomed Res Int ; 2015: 248976, 2015.
Article in English | MEDLINE | ID: mdl-26347229

ABSTRACT

Neuronal apoptosis inhibitory protein (NAIP) and survivin might play an important role in testicular function. We investigated the effect of PDRN, an agonist of adenosine A2A receptor, on testicular NAIP and survivin expression in an experimental model of varicocele. After the creation of experimental varicocele (28 days), adolescent male Sprague-Dawley rats were randomized to one of the following treatments lasting 21 days: vehicle, PDRN (8 mg/kg i.p., daily), PDRN + 3,7-dimethyl-propargylxanthine (DMPX, a specific adenosine A2A-receptor antagonist, 0.1 mg/kg i.p., daily), varicocelectomy, and varicocelectomy + PDRN (8 mg/kg i.p., daily). Sham-operated animals were used as controls. Animals were then euthanized and testis expression of NAIP and survivin was evaluated through qRT-PCR, western blot, and immunohistochemical analysis. Spermatogenetic activity was also assessed. NAIP and survivin expressions were significantly reduced following varicocele induction when compared to sham animals whereas PDRN-treated rats showed an increase in NAIP and survivin levels. Immunohistochemistry revealed an enhanced expression of NAIP and survivin with a characteristic pattern of cellular localization following PDRN treatment. Moreover, administration of PDRN significantly restored spermatogenic function in varicocele rats. PDRN may represent a rational therapeutic option for accelerating recovery from depressed testicular function through a strategic modulation of apoptosis in experimental varicocele.


Subject(s)
Fertility/drug effects , Microtubule-Associated Proteins/biosynthesis , Neuronal Apoptosis-Inhibitory Protein/biosynthesis , Oligodeoxyribonucleotides/pharmacology , Testis/metabolism , Varicocele/metabolism , Adenosine A2 Receptor Antagonists/pharmacology , Animals , Disease Models, Animal , Gene Expression Regulation/drug effects , Male , Rats , Receptors, Adenosine A2/metabolism , Spermatogenesis/drug effects , Survivin , Testis/pathology , Theobromine/analogs & derivatives , Theobromine/pharmacology , Varicocele/pathology
19.
Neuromolecular Med ; 17(2): 192-201, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25893744

ABSTRACT

Systemic administration of kainic acid causes inflammation and apoptosis in the brain, resulting in neuronal loss. Dual cyclooxygenase/5-lipoxygenase (COX/5-LOX) inhibitors could represent a possible neuroprotective approach in preventing glutamate excitotoxicity. Consequently, we investigated the effects of a dual inhibitor of COX/5-LOX following intraperitoneal administration of kainic acid (KA, 10 mg/kg) in rats. Animals were randomized to receive either the dual inhibitor of COX/5-LOX (flavocoxid, 20 mg/kg i.p.) or its vehicle (1 ml/kg i.p.) 30 min after KA administration. Sham brain injury rats were used as controls. We evaluated protein expression of phosphorylated extracellular signal-regulated kinase (p-ERK1/2) and tumor necrosis factor alpha (TNF-α) as well as levels of malondialdehyde (MDA), prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) in the hippocampus. Animals were also observed for monitoring behavioral changes according to Racine Scale. Finally, histological analysis and brain edema evaluation were carried out. Treatment with the dual inhibitor of COX/5-LOX decreased protein expression of p-ERK1/2 and TNF-α in hippocampus, markedly reduced MDA, LTB4 and PGE2 hippocampal levels, and also ameliorated brain edema. Histological analysis showed a reduction in cell damage in rats treated with the dual inhibitor of COX/5-LOX, particularly in hippocampal subregion CA3c. Moreover, flavocoxid significantly improved behavioral signs following kainic acid administration. Our results suggest that dual inhibition of COX/5-LOX by flavocoxid has neuroprotective effects during kainic acid-induced excitotoxicity.


Subject(s)
Brain Edema/prevention & control , Catechin/therapeutic use , Cyclooxygenase Inhibitors/therapeutic use , Lipoxygenase Inhibitors/therapeutic use , Neuroprotective Agents/therapeutic use , Seizures/prevention & control , Animals , Behavior, Animal/drug effects , Brain Edema/chemically induced , Brain Edema/enzymology , Brain Edema/pathology , Catechin/pharmacology , Cyclooxygenase Inhibitors/pharmacology , Dinoprostone/analysis , Drug Combinations , Hippocampus/chemistry , Hippocampus/drug effects , Hippocampus/pathology , Kainic Acid/toxicity , Leukotriene B4/analysis , Lipid Peroxidation/drug effects , Lipoxygenase Inhibitors/pharmacology , MAP Kinase Signaling System/drug effects , Male , Malondialdehyde/analysis , Nerve Tissue Proteins/antagonists & inhibitors , Neuroprotective Agents/pharmacology , Neurotoxins/toxicity , Phosphorylation , Protein Processing, Post-Translational/drug effects , Random Allocation , Rats , Rats, Sprague-Dawley , Seizures/chemically induced , Seizures/enzymology , Seizures/pathology , Tumor Necrosis Factor-alpha/metabolism
20.
Toxicol Sci ; 148(1): 311-29, 2015 11.
Article in English | MEDLINE | ID: mdl-26424772

ABSTRACT

Cadmium (Cd) causes male infertility. There is the need to identify safe treatments counteracting this toxicity. Flavocoxid is a flavonoid that induces a balanced inhibition of cyclooxygenase (COX)-1 and COX-2 peroxidase moieties and of 5-lipoxygenase (LOX) and has efficacy in the male genitourinary system. We investigated flavocoxid effects on Cd-induced testicular toxicity in mice. Swiss mice were divided into 4 groups: 2 control groups received 0.9% NaCl (vehicle; 1 ml/kg/day) or flavocoxid (20 mg/kg/day ip); 2 groups were challenged with cadmium chloride (CdCl2; 2 mg/kg/day ip) and administered with vehicle or flavocoxid. The treatment lasted for 1 or 2 weeks. The testes were processed for biochemical and morphological studies. CdCl2 increased phosphorylated extracellular signal-regulated kinase (p-ERK) 1/2, tumor necrosis factor (TNF)-α, COX-2, 5-LOX, malondialdehyde (MDA), B-cell-lymphoma (Bcl)-2-associated X protein (Bax), follicle-stimulating hormone (FSH), luteinizing hormone (LH), transforming growth factor (TGF) -ß3, decreased Bcl-2, testosterone, inhibin-B, occludin, N-Cadherin, induced structural damages in the testis and disrupted the blood-testis barrier. Many TUNEL-positive germ cells and changes in claudin-11, occludin, and N-cadherin localization were present. Flavocoxid administration reduced, in a time-dependent way, p-ERK 1/2, TNF-α, COX-2, 5-LOX, MDA, Bax, FSH, LH, TGF-ß3, augmented Bcl-2, testosterone, inhibin B, occludin, N-Cadherin, and improved the structural organization of the testis and the blood-testis barrier. Few TUNEL-positive germ cells were present and a morphological retrieval of the intercellular junctions was observed. In conclusion, flavocoxid has a protective anti-inflammatory, antioxidant, and antiapoptotic function against Cd-induced toxicity in mice testis. We suggest that flavocoxid may play a relevant positive role against environmental levels of Cd, otherwise deleterious to gametogenesis and tubular integrity.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Blood-Testis Barrier/drug effects , Cadmium Poisoning/prevention & control , Catechin/therapeutic use , Infertility, Male/prevention & control , Seminiferous Tubules/drug effects , Spermatogenesis/drug effects , Animals , Antioxidants/therapeutic use , Apoptosis/drug effects , Biomarkers/metabolism , Blood-Testis Barrier/metabolism , Blood-Testis Barrier/pathology , Blood-Testis Barrier/ultrastructure , Cadherins/agonists , Cadherins/antagonists & inhibitors , Cadherins/metabolism , Cadmium Poisoning/metabolism , Cadmium Poisoning/pathology , Cadmium Poisoning/physiopathology , Drug Combinations , Infertility, Male/etiology , Lipid Peroxidation/drug effects , Male , Mice, Inbred C57BL , Occludin/agonists , Occludin/antagonists & inhibitors , Occludin/metabolism , Oxidative Stress/drug effects , Phosphorylation/drug effects , Protein Processing, Post-Translational/drug effects , Seminiferous Tubules/metabolism , Seminiferous Tubules/pathology , Seminiferous Tubules/ultrastructure , Tight Junctions/drug effects , Tight Junctions/metabolism , Tight Junctions/pathology , Tight Junctions/ultrastructure
SELECTION OF CITATIONS
SEARCH DETAIL